Efficacy and Safety of Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin and Prednisone for Previously Untreated Diffuse Large B‐Cell Lymphoma: A Real‐World, Multi‐Center, Retrospective Cohort Study
Hematological Oncology · 2025-01 · 43 (1)
DOI: 10.1002/hon.70017 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Hematological Oncology, online erschienen am 06.12.2024. Verfasst von Peiqi Zhao und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Lymphoma, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, National Clinical Research Ce…. Hauptthemen laut MEDLINE: Lymphoma, Large B-Cell, Diffuse, Cyclophosphamide, Antineoplastic Combined Chemotherapy Protocols, Rituximab. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 31 Literaturangaben.
Abstract (Originalsprache)
Polatuzumab vedotin plus R‐CHP (Pola‐R‐CHP) is approved as a new standard first‐line therapy for diffuse large B‐cell lymphoma (DLBCL) based on the POLARIX trial. However, real‐world data on its efficacy and safety in unselected patients is lacking. We conducted a retrospective cohort study to evaluate Pola‐R‐CHP versus R‐CHOP outcomes in routine clinical practice in China. This is a multi‐institutional retrospective cohort study and included all consecutive patients that received at least one dose of polatuzumab vedotin up until February 2024. A total of 600 eligible patients from 6 centers were identified, 131 receiving Pola‐R‐CHP and 469 R‐CHOP. After 1:2 propensity score matching, 128 pairs were obtained for further survival and prognosis analysis. With a median follow‐up of 12.8 months, 12‐month progression‐free survival (PFS) was numerically higher with Pola‐R‐CHP versus R‐CHOP (90.3% vs. 84.1%, p = 0.18). Benefits were consistently observed across molecular subgroups, especially advanced stage, ECOG ≥ 2, extranodal involvement ≥ 2 and non‐GCB group. The complete response rate of the Pola‐R‐CHP group was higher than that of the RCHOP group (86.8% vs. 79.7%; p = 0.09), but there was no statistical difference. Safety profiles were comparable, with no new concerns. Among 128 patients treated with Pola‐R‐CHP, 96 underwent gene sequencing analysis: MCD (25.0%), EZB (13.5%), combined subtype (12.5%), ST2 (9.4%), and other/unclassifiable subtype (30.2%). The most common mutations (> 25% of cases) were PIM1, TP53, BCL‐6, KMT2D, SOCS1, BCL‐2. Genetic testing results show the correlation between genotyping, gene mutations in PIM1/TP53 and therapeutic efficacy. This large real‐world study supports Pola‐R‐CHP as an effective frontline option for DLBCL, with sustained efficacy versus R‐CHOP observed in unselected populations. While 12‐month PFS failed to reach statistical significance, subgroup analyses favor Pola‐R‐CHP. Further research with a wider population, longer follow‐up, and screening of advantageous groups are warranted.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Lymphoma, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospi…
- Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin Medical University, Harbin, China.
- Department of Hematology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
- Department of Lymphoma and Hematology, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University/Hunan Cancer Hospital, Changsha, China.
- Department of Lymphoma & Head and Neck Oncology, College of Clinical Medicine for Oncology, Fujian Medical University, Fuzhou, China.
- Department of Hematology, Yantai Yuhuangding Hospital Affiliated to Qingdao University, Yantai, China.
ORCID-Profile: Peiqi Zhao, Yajun Li, Qingyuan Zhang, Huilai Zhang
Zitieren
APA
Zhao, P., Zhao, S., Huang, C., Li, Y., Wang, J., Xu, J., Li, L., Qian, Z., Li, W., Zhou, S., Qiu, L., Liu, X., Chen, Y., Jiang, Y., Zheng, Y., Chen, D., Zhou, H., Gao, Y., Zhang, Q., & Zhang, H. (2025). Efficacy and Safety of Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin and Prednisone for Previously Untreated Diffuse Large B‐Cell Lymphoma: A Real‐World, Multi‐Center, Retrospective Cohort Study. Hematological Oncology, 43(1). https://doi.org/10.1002/hon.70017
Vancouver
Zhao P, Zhao S, Huang C, Li Y, Wang J, Xu J, et al. Efficacy and Safety of Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin and Prednisone for Previously Untreated Diffuse Large B‐Cell Lymphoma: A Real‐World, Multi‐Center, Retrospective Cohort Study. Hematological Oncology. 2025;43(1). doi:10.1002/hon.70017
BibTeX
@article{Zhao2025,
author = {Zhao, Peiqi and Zhao, Shu and Huang, Chen and Li, Yajun and Wang, Jiesong and Xu, Junqing and Li, Lanfang and Qian, Zhengzi and Li, Wei and Zhou, Shiyong and Qiu, Lihua and Liu, Xianming and Chen, Ying and Jiang, Yanan and Zheng, Yanbin and Chen, Daoguang and Zhou, Hui and Gao, Yuhuan and Zhang, Qingyuan and Zhang, Huilai},
title = {Efficacy and Safety of Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin and Prednisone for Previously Untreated Diffuse Large B‐Cell Lymphoma: A Real‐World, Multi‐Center, Retrospective Cohort Study},
journal = {Hematological Oncology},
year = {2025},
volume = {43},
number = {1},
doi = {10.1002/hon.70017}
}
EUVIMED